CRVS Stock Summary and Trading Ideas (Corvus Pharmaceuticals | NASDAQ:CRVS)

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Corvus Pharmaceuticals trades on the NASDAQ stock market under the symbol CRVS.

As of November 6, 2026, CRVS stock price climbed to $10.54 with 1,172,814 million shares trading.

CRVS has a beta of 0.96, meaning it tends to be less sensitive to market movements. CRVS has a correlation of 0.01 to the broad based SPY ETF.

CRVS has a market cap of $886.31 million. This is considered a Small Cap stock.

In the last 3 years, CRVS traded as high as $26.95 and as low as $1.23.

The top ETF exchange traded funds that CRVS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

CRVS has outperformed the market in the last year with a price return of +34.8% while the SPY ETF gained +10.8%. However, in the short term, CRVS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -24.0% vs -4.1% return in SPY. But in the last 2 weeks, CRVS shares have fared better than the market returning +0.1% compared to SPY -3.2%.

CRVS support price is $9.33 and resistance is $10.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVS shares will trade within this expected range on the day.